Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Biogen Idec Inc (BIIB) and Gilead Sciences, Inc. (GILD) Two of the Three Hottest Biotech Stocks You Must Own

Biogen Idec Inc (NASDAQ:BIIB) and Gilead Sciences, Inc. (NASDAQ:GILD) are two of the hottest stocks in biotech today, and should be jumped on now according to Allianz Global Investors analyst John Schroer. He broke down the two stocks on CNBC on Friday beginning with Biogen Idec Inc (NASDAQ:BIIB), whose explosive growth is very appealing.

Gilead Sciences, Inc. (NASDAQ:GILD)

“First one would be Biogen. Leading company in the MS (multiple sclerosis) space. They have some very strong earnings growth, 20 to 25% earnings growth over the next three years, and we’re looking at a valuation that’s just below 25 times, so it’s a very attractive name,” Schroer said.

In Biogen’s most recently reported quarter, their fiscal second quarter ending June 30, the company had revenue of $2.42 billion that greatly exceeded analysts’ expectations, and which equaled a 40.5% jump from the same quarter last year.

For Gilead Sciences, Inc. (NASDAQ:GILD) the news today wasn’t necessarily ideal, as the stock tumbled on word that there would be pricing pressures on Hepatitis C drugs. The same news adversely affected the stock back in March and April, from which it rebounded and rose more than 50% in the following months.

Schroer expects a similar rebound for Gilead Sciences, Inc. (NASDAQ:GILD) from the current news as well, and that the stock still has plenty of upward momentum left in it despite the news and despite its rapid ascent over the past few months. Trading at just 11 times consensus earnings, and with those earnings on the verge of greatly increasing, Gilead remains a strong choice.

Though not specifically discussed during the segment by Schroer, it was also shown that Celgene Corporation (NASDAQ:CELG) was his third choice as a must-own biotech stock. Celgene Corporation (NASDAQ:CELG) on Thursday released positive results from their late-stage clinical trial of REVLIMID as a combination treatment for multiple myeloma patients who are ineligible for stem cell transplants.

Disclosure: none

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!